Targacept, a developer of a new class of drugs to treat Alzheimer's and cognitive loss, priced 5.0 million shares at $9 Monday evening, below its original $11 to $13 range. Deutsche Bank and Pacific Growth Equities were the lead managers on the deal. Expect...read more
Targacept, a developer of a new class of drugs to treat central nervous system diseases, announced Thursday that it will offer 5.0 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market...read more
Targacept, a biopharmaceutical company developing a new class of drugs to treat central nervous system and other diseases, filed an S-1 registration statement for the second time. The Winston-Salem, NC based firm tried to go public in February 2005 but...read more
Targacept filed a request to withdraw its initial public offering on Wednesday. The company, which develops a new class of drugs to treat central nervous system disorders, cited difficult market conditions as the reason for withdrawing the offering. Targacept...read more
Drug developer Targacept prices at $9
Targacept, a developer of a new class of drugs to treat Alzheimer's and cognitive loss, priced 5.0 million shares at $9 Monday evening, below its original $11 to $13 range. Deutsche Bank and Pacific Growth Equities were the lead managers on the deal. Expect...read more
Drug developer Targacept sets terms
Targacept, a developer of a new class of drugs to treat central nervous system diseases, announced Thursday that it will offer 5.0 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market...read more
Biopharmaceutical firm Targacept makes second attempt to go public
Targacept, a biopharmaceutical company developing a new class of drugs to treat central nervous system and other diseases, filed an S-1 registration statement for the second time. The Winston-Salem, NC based firm tried to go public in February 2005 but...read more
Targacept withdraws application for IPO
Targacept filed a request to withdraw its initial public offering on Wednesday. The company, which develops a new class of drugs to treat central nervous system disorders, cited difficult market conditions as the reason for withdrawing the offering. Targacept...read more